MANGOCEUTICALS, INC. Announces Board Changes and Compensatory Arrangements
Ticker: MGRX · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
MANGOCEUTICALS board shakeup: Director out, new directors in, plus executive pay details.
AI Summary
On March 25, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing several key events. The company announced the departure of Director David L. Schull and the election of new directors, including Dr. David L. Schull and Dr. David L. Schull, to its board. Additionally, the filing covers compensatory arrangements for certain officers and the submission of matters to a vote of security holders.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and executive compensation adjustments can introduce uncertainty regarding future strategy and leadership stability.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- David L. Schull (person) — Departing Director
- Dr. David L. Schull (person) — Newly Elected Director
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
FAQ
Who has departed from the MANGOCEUTICALS, INC. board of directors?
Director David L. Schull has departed from the MANGOCEUTICALS, INC. board of directors.
Who has been elected to the MANGOCEUTICALS, INC. board of directors?
Dr. David L. Schull and Dr. David L. Schull have been elected to the MANGOCEUTICALS, INC. board of directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 25, 2024.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive office address is 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What are the main topics covered in this 8-K filing?
This filing covers the departure of directors, election of directors, compensatory arrangements of certain officers, and submission of matters to a vote of security holders.
Filing Stats: 1,423 words · 6 min read · ~5 pages · Grade level 11.4 · Accepted 2024-03-26 17:28:40
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 59KB
- ex10-1.htm (EX-10.1) — 13KB
- ex10-2.htm (EX-10.2) — 266KB
- 0001493152-24-011360.txt ( ) — 564KB
- mgrx-20240325.xsd (EX-101.SCH) — 3KB
- mgrx-20240325_lab.xml (EX-101.LAB) — 33KB
- mgrx-20240325_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: March 26, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer